Pfizer Total Current Liabilities 2010-2024 | PFE
Pfizer total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Pfizer total current liabilities for the quarter ending September 30, 2024 were $43.211B, a 38.78% increase year-over-year.
- Pfizer total current liabilities for 2023 were $47.794B, a 13.42% increase from 2022.
- Pfizer total current liabilities for 2022 were $42.138B, a 1.25% decline from 2021.
- Pfizer total current liabilities for 2021 were $42.671B, a 64.63% increase from 2020.
Pfizer Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$47,794 |
| 2022 |
$42,138 |
| 2021 |
$42,671 |
| 2020 |
$25,920 |
| 2019 |
$37,304 |
| 2018 |
$31,858 |
| 2017 |
$30,427 |
| 2016 |
$31,115 |
| 2015 |
$29,399 |
| 2014 |
$21,587 |
| 2013 |
$23,366 |
| 2012 |
$29,186 |
| 2011 |
$28,909 |
| 2010 |
$28,636 |
| 2009 |
$37,225 |
Pfizer Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$43,211 |
| 2024-06-30 |
$43,819 |
| 2024-03-31 |
$40,497 |
| 2023-12-31 |
$47,794 |
| 2023-09-30 |
$31,136 |
| 2023-06-30 |
$34,647 |
| 2023-03-31 |
$36,562 |
| 2022-12-31 |
$42,138 |
| 2022-09-30 |
$44,314 |
| 2022-06-30 |
$47,410 |
| 2022-03-31 |
$39,268 |
| 2021-12-31 |
$42,671 |
| 2021-09-30 |
$41,803 |
| 2021-06-30 |
$35,664 |
| 2021-03-31 |
$26,652 |
| 2020-12-31 |
$25,920 |
| 2020-09-30 |
$34,154 |
| 2020-06-30 |
$32,723 |
| 2020-03-31 |
$33,890 |
| 2019-12-31 |
$37,304 |
| 2019-09-30 |
$36,974 |
| 2019-06-30 |
$32,030 |
| 2019-03-31 |
$29,423 |
| 2018-12-31 |
$31,858 |
| 2018-09-30 |
$29,013 |
| 2018-06-30 |
$32,156 |
| 2018-03-31 |
$27,365 |
| 2017-12-31 |
$30,427 |
| 2017-09-30 |
$28,217 |
| 2017-06-30 |
$27,182 |
| 2017-03-31 |
$24,864 |
| 2016-12-31 |
$31,115 |
| 2016-09-30 |
$34,759 |
| 2016-06-30 |
$32,099 |
| 2016-03-31 |
$28,735 |
| 2015-12-31 |
$29,399 |
| 2015-09-30 |
$27,845 |
| 2015-06-30 |
$24,143 |
| 2015-03-31 |
$20,222 |
| 2014-12-31 |
$21,587 |
| 2014-09-30 |
$19,920 |
| 2014-06-30 |
$21,938 |
| 2014-03-31 |
$24,790 |
| 2013-12-31 |
$23,366 |
| 2013-09-30 |
$20,373 |
| 2013-06-30 |
$23,450 |
| 2013-03-31 |
$27,543 |
| 2012-12-31 |
$29,186 |
| 2012-09-30 |
$29,131 |
| 2012-06-30 |
$30,798 |
| 2012-03-31 |
$27,094 |
| 2011-12-31 |
$28,909 |
| 2011-09-30 |
$27,856 |
| 2011-06-30 |
$30,471 |
| 2011-03-31 |
$29,171 |
| 2010-12-31 |
$28,636 |
| 2010-09-30 |
$24,172 |
| 2010-06-30 |
$24,681 |
| 2010-03-31 |
$25,924 |
| 2009-12-31 |
$37,225 |
| 2009-09-30 |
$23,992 |
| 2009-06-30 |
$26,109 |
| 2009-03-31 |
$23,340 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.358B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
